Intralesional Triamcinolone Acetonide Dosage for Keloid Treatment
For keloid treatment in adults, inject triamcinolone acetonide at a concentration of 40 mg/mL (TAC-40), administering 0.05–0.1 mL per injection site every 3–4 weeks until maximum therapeutic response is achieved. 1
Standard Dosing Protocol
Concentration Selection
- TAC-40 (40 mg/mL) is the standard concentration for keloid treatment 1
- For smaller or thinner lesions, lower concentrations of 5–10 mg/mL may be used to reduce atrophy risk 1
- Very thick or non-responding lesions may require concentrations up to 20 mg/mL 1, 2, 3
Injection Volume and Technique
- Inject 0.05–0.1 mL per site, which treats approximately 0.5 cm diameter of keloid tissue 1
- Place the needle just beneath the dermis in the upper subcutis to maximize local effect and minimize systemic absorption 1
- Multiple injection sites should be distributed evenly throughout the entire keloid 1
- Inject until the tissue blanches (whitens), indicating adequate intralesional delivery 4
Treatment Schedule
- Administer injections every 3–4 weeks 1
- Continue treatment until maximum therapeutic response is observed 1
- The beneficial effect typically persists for approximately 9 months after a treatment course 1
Maximum Dosing Limits
The maximum dose per session varies in the literature from 20 to 80 mg total, though specific limits are not uniformly established 4. Patient discomfort is often the primary limiting factor for the number of injection sites per session 1.
Combination Therapy Considerations
While monotherapy is effective, combining triamcinolone acetonide with 5-fluorouracil (5-FU) demonstrates superior efficacy with fewer side effects compared to triamcinolone alone 5, 2, 6. When using combination therapy:
- Mix TAC 40 mg/mL with 5-FU 50 mg/mL in a 1:1 ratio, or use TAC 20 mg/mL with 5-FU 25 mg/mL 5, 2, 6
- This combination produces faster response rates (95% good-to-excellent response vs. 70% with TAC alone) 5
- Combination therapy reduces atrophy and telangiectasia compared to TAC monotherapy 5, 7
Safety Profile and Adverse Effects
Common Side Effects
- Skin atrophy is the most consistent adverse effect, particularly with higher concentrations 1
- Telangiectasia (visible blood vessels) occurs frequently with TAC monotherapy (37% in some studies) 7, 6
- Hypopigmentation may develop at injection sites 7
- Pain during injection is common and limits the number of sites treatable per session 1
Risk Mitigation
- Using lower concentrations (5–10 mg/mL) with the small-volume technique (0.05–0.1 mL per site) reduces atrophy incidence 1
- Injecting just beneath the dermis rather than deeper minimizes systemic absorption and complications 1
Contraindications
Intralesional triamcinolone should be avoided in patients with:
- Active infection at the injection site (impetigo, herpes) 1
- Known hypersensitivity to triamcinolone 1
- Active tuberculosis or systemic fungal infection when large-volume injections are planned 1
- Uncontrolled diabetes, heart failure, or severe hypertension 1
Practical Administration Tips
- Needle size: 25–27 gauge needles are commonly used 8, 4
- Syringe size: 1 mL syringes provide better control for small-volume injections 4
- Consider premedication with topical anesthetics (e.g., EMLA cream) to reduce injection pain 8
- Needle-free delivery systems (e.g., Dermajet) are acceptable alternatives to conventional syringes 1
- Local anesthetics are used in only 20% of published trials, though they may improve patient tolerance 4
Expected Outcomes
Clinical improvement generally requires multiple treatment sessions 1. Response rates vary:
- With TAC monotherapy: 70% achieve good-to-excellent response 5
- With TAC + 5-FU combination: 95% achieve good-to-excellent response 5
- Significant reduction in keloid height, pliability, pain, and itching occurs after repeated sessions 2, 3
Critical Pitfall
Most studies have inadequate follow-up periods (only 6 of 38 RCTs had ≥6 months follow-up), making true recurrence rates difficult to establish 4. Long-term monitoring beyond the treatment period is essential to detect recurrence, which can occur even after apparent resolution 4.